(Q33413742)

English

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

author name string

Xichun Hu

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jian Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Binghe Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Zefei Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joseph Ragaz

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Zhongsheng Tong

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Qingyuan Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xiaojia Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jifeng Feng

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Danmei Pang

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Minhao Fan

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jin Li

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Biyun Wang

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Zhonghua Wang

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Qunling Zhang

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Si Sun

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chunmei Liao

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

20 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

135

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1961-1969

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Molecular stratification of triple-negative breast cancers.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Survivin expression quantified by Image Pro-Plus compared with visual assessment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phase II open-label study of sunitinib in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Contrasting effects of sunitinib within in vivo models of metastasis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28829

21 January 2018

Identifiers

10.1002/IJC.28829

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33413742&oldid=1968716038"